NCT02252263 · Interventional trial
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Overall registry status Completed
Phase 1
Conditions Multiple Myeloma
Delaware Valley sites
- University Of Pennsylvania · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory